Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
190 studies found for:    "Poliomyelitis"
Show Display Options
Rank Status Study
21 Completed Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults
Condition: Poliomyelitis
Interventions: Drug: IPV;   Drug: Sabin-IPV;   Drug: Adjuvanted Sabin-IPV
22 Completed Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV
Conditions: Poliomyelitis;   Polio
Interventions: Biological: Poliomyelitis Vaccine inactivated;   Biological: Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell)
23 Recruiting Safety and Immunogenicity of IPOVAC in Young Children
Condition: Poliomyelitis
Interventions: Biological: IMOVAC-POLIO;   Biological: IPOVAC 1.5:5:5;   Biological: IPOVAC, 3:10:10;   Biological: IPOVAC, 6:20:20
24 Completed Polio NID and Routine EPI Integration Trial Pakistan
Condition: Polio
Interventions: Behavioral: Vaccine promotion messages;   Other: Vaccination Verification.;   Other: Distribution of Plastic Pouches to retain vaccination card
25 Completed A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children
Condition: Poliomyelitis
Intervention: Biological: Poliomyelitis vaccine (inactivated) -PoliorixTM
26 Completed Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules
Condition: Poliomyelitis
Interventions: Biological: bOPV (three dose);   Biological: bOPV (two dose);   Biological: IPV
27 Completed Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine
Condition: Poliomyelitis
Interventions: Biological: Bivalent Oral Polio Vaccine (bOPV);   Biological: Trivalent Oral Polio Vaccine (tOPV);   Biological: Monovalent Oral Polio Vaccine Type 2 (mOPV2);   Biological: Sanofi-Pasteur IPV (Sanofi IPV);   Biological: Glaxo SmithKline IPV (GSK IPV);   Biological: Serum Institute of India IPV (SII IPV)
28 Enrolling by invitation Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio Vaccine
Condition: Poliomyelitis
Interventions: Biological: IPV;   Biological: OPV
29 Unknown  Study of Mental Fatigue in Polio Survivors
Condition: Post-Poliomyelitis Syndrome
Intervention:
30 Not yet recruiting A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania
Condition: Poliomyelitis
Intervention: Biological: Sabin mOPV2
31 Not yet recruiting A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age
Condition: Poliomyelitis
Intervention: Biological: Oral Polio Vaccine
32 Completed
Has Results
Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects
Condition: Polio Immunity
Intervention: Drug: IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose
33 Completed Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults
Condition: Poliomyelitis
Interventions: Biological: a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD);   Biological: a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).
34 Completed Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers
Condition: Poliomyelitis
Intervention: Biological: PoliorixTM
35 Completed Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants
Condition: Poliomyelitis
Interventions: Drug: IPV;   Drug: Low dose Sabin-IPV;   Drug: Low dose adjuvanted Sabin-IPV;   Drug: Middle dose Sabin-IPV;   Drug: Middle dose adjuvanted Sabin-IPV;   Drug: High dose Sabin-IPV;   Drug: High dose adjuvanted Sabin-IPV
36 Completed Study of "Post-Polio Syndrome"
Conditions: Poliomyelitis;   Postpoliomyelitis Syndrome
Intervention:
37 Recruiting L-Citrulline in Patients With Post-Polio Syndrome
Condition: Post-Polio Syndrome
Interventions: Drug: 15g L-citrulline daily p.o.;   Drug: Placebo
38 Completed Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine
Condition: Poliomyelitis
Interventions: Biological: mOPV2 at 6 and 7 weeks of age;   Biological: mOPV2 at 6 and 8 weeks of age;   Biological: mOPV2 at 6 and 10 weeks of age;   Biological: IPV at 6 weeks of age
39 Completed Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine
Condition: Poliomyelitis
Interventions: Biological: bOPV/IPV (6 weeks);   Biological: bOPV/IPV (14 weeks);   Biological: bOPV/IPV (6 & 14 weeks)
40 Recruiting A Clinical Study Comparing Safety and Immunogenicity of Bivalent Oral Polio Vaccine (bOPV) of Bilthoven Biologicals (BBio) With a Licensed bOPV
Condition: Immune Response to Oral Polio Vaccine
Interventions: Biological: Part 1 study - BBio bOPV;   Biological: Part 2 study - BBio bOPV Lot 1;   Biological: Part 2 study - BBio bOPV Lot 2;   Biological: Part 2 study - BBio bOPV Lot 3;   Biological: Part 2 study - Licensed bOPV;   Biological: Part 1 study - Licensed bOPV

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.